4.3 Irradiated Components

Why Irradiate: Preventing TA-GVHD

Irradiation of cellular blood components exists for one purpose: to inactivate donor T-lymphocytes so they cannot proliferate and cause transfusion-associated graft-versus-host disease (TA-GVHD). Unlike graft-versus-host disease after stem cell transplant, TA-GVHD occurs when viable, immunocompetent donor lymphocytes in a transfused blood component engraft in a recipient who cannot reject them — either because the recipient is severely immunocompromised, or because the donor and recipient share enough HLA haplotypes (as in first- or second-degree relative directed donations) that the recipient's immune system does not recognize the donor lymphocytes as foreign, even though the donor lymphocytes recognize the recipient as foreign and attack.

TA-GVHD is rare (well under one per million transfusions in current practice) but carries a fatality rate exceeding 90%. Clinically, it presents 4-30 days post-transfusion with fever, an erythematous or desquamating rash, watery diarrhea, liver dysfunction (elevated transaminases/bilirubin), and — the classic distinguishing feature from other forms of GVHD — pancytopenia from marrow involvement, because the engrafted donor lymphocytes attack recipient marrow stem cells in addition to skin, gut, and liver.

Who Needs Irradiated Components

Exam trap: irradiation is required for all granulocyte transfusions, regardless of the recipient's underlying diagnosis, because granulocyte concentrates cannot be leukoreduced without destroying the therapeutic granulocytes, leaving a comparatively high, unavoidable lymphocyte load.

Irradiation Dose and Technology

AABB Standards and FDA guidance specify a minimum central (mid-plane) dose of 25 Gray (Gy) — equivalently 2,500 cGy — with no portion of the unit receiving less than 15 Gy. No formal AABB upper limit exists, though a practical ceiling near 50 Gy is widely used to avoid excess red cell membrane damage; doses above this range begin to compromise red cell integrity without adding meaningful lymphocyte-inactivation benefit.

Two irradiator technologies are FDA-cleared or approved. Gamma irradiators use a sealed cesium-137 or cobalt-60 radioactive source; they are highly reliable and deliver consistent dosing but require extensive Nuclear Regulatory Commission licensing, security, and disposal oversight, and dose delivery time slowly lengthens as the source decays. X-ray irradiators generate radiation electronically with no radioactive source, avoiding source-security requirements and offering more flexible siting, at the cost of different dosimetry validation needs.

Both technologies require annual (or post-repair/post-reload) dosimetric mapping: dosimeter chips placed throughout a dummy load confirm that the coldest point in the irradiation chamber still receives at least 15 Gy while the center receives at least 25 Gy — a direct, practical application of the dose-distribution standard above.

Effect on Red Blood Cell Storage: The Shortened Outdate

Irradiation damages the red cell membrane, accelerating potassium leakage into the supernatant beyond the rate seen in non-irradiated storage. Because rapid, large-volume infusion of a high-potassium unit is a real hyperkalemia risk, especially in neonates or renally impaired patients, AABB Standards require that an irradiated Red Blood Cell unit expire 28 days after the date of irradiation, or on the unit's original expiration date, whichever comes first. A unit irradiated early in storage will outdate 28 days later. A unit irradiated near its natural outdate (for example, day 35 of a 42-day AS-3 unit) will outdate at its original day-42 mark, not 28 days later, because whichever date is sooner governs.

Platelets are treated differently. Irradiation does not meaningfully accelerate the biochemical processes that limit platelet shelf life, so an irradiated platelet unit keeps its original expiration date (typically 5-7 days) — the SBB should not apply the RBC 28-day rule to platelets.

Irradiation Does Not Address CMV

A frequently tested distinction: irradiation inactivates T-lymphocyte proliferative capacity but does not inactivate cytomegalovirus (CMV), which remains latent within leukocytes independent of their ability to divide. A component can be irradiated and still transmit CMV. For a CMV-seronegative, at-risk recipient (a seronegative pregnant patient, a seronegative transplant candidate or recipient, or a low-birth-weight neonate), the appropriate CMV-risk-reduction strategies are a CMV-seronegative donor unit or a leukocyte-reduced unit — irradiation alone accomplishes neither.

Confirming Irradiation Occurred

Irradiated units carry a distinct label, and many facilities use a chemical irradiation indicator — a label that undergoes a visible color change once it has received an adequate dose — as a secondary visual confirmation alongside dosimetry records, helping prevent accidental release of a non-irradiated unit intended for an at-risk recipient.

Regulatory and Quality Control Considerations

Because a gamma irradiator contains a licensed radioactive source, the facility operating it must maintain an NRC (or Agreement State) radioactive materials license, perform routine leak testing of the sealed source, and enroll operators in a radiation safety and personnel dosimetry program. Every irradiation cycle is logged with the unit identifier, date, time, dose, and irradiator identification, creating a permanent quality record that a reviewer or inspector can trace from donor unit to recipient. X-ray irradiators remove the sealed-source licensing burden but still require the same cycle-by-cycle dose documentation and periodic output verification against a calibrated dosimetry standard.

When a facility receives an irradiated component from an outside supplier rather than irradiating in-house, the receiving blood bank must still confirm the irradiation label, the irradiation date, and the resulting 28-day-or-sooner expiration before the unit is released for an at-risk recipient — irradiation status is a component attribute the SBB must verify at every handoff, not something that can be assumed from the order alone.